DURAVYU™ (EYP-1901)
Wet Age-Related Macular Degeneration (Wet AMD)
Key Facts
About EyePoint Pharmaceuticals
EyePoint Pharmaceuticals is focused on redefining the treatment paradigm for serious retinal diseases by creating best-in-class, durable therapies that aim to improve patient outcomes while reducing treatment burden. The company leverages its proprietary Durasert E™ sustained-release technology, which has a proven safety profile across four FDA-approved products. Its lead pipeline asset, DURAVYU™ (vorolanib in Durasert E™), is a novel multi-mechanism tyrosine kinase inhibitor being developed for wet AMD and DME, with pivotal trial readouts expected in 2026. EyePoint is a publicly traded company (NASDAQ: EYPT) led by an experienced team of ophthalmology and biopharmaceutical executives.
View full company profileAbout EyePoint Pharmaceuticals
EyePoint Pharmaceuticals is focused on redefining the treatment paradigm for serious retinal diseases by creating best-in-class, durable therapies that aim to improve patient outcomes while reducing treatment burden. The company leverages its proprietary Durasert E™ sustained-release technology, which has a proven safety profile across four FDA-approved products. Its lead pipeline asset, DURAVYU™ (vorolanib in Durasert E™), is a novel multi-mechanism tyrosine kinase inhibitor being developed for wet AMD and DME, with pivotal trial readouts expected in 2026. EyePoint is a publicly traded company (NASDAQ: EYPT) led by an experienced team of ophthalmology and biopharmaceutical executives.
View full company profileTherapeutic Areas
Other Wet Age-Related Macular Degeneration (Wet AMD) Drugs
| Drug | Company | Phase |
|---|---|---|
| OTX-TKI (axitinib implant) | Ocular Therapeutix | Phase 3 |
| Sozinibercept (OPT-302) | Opthea | Phase 3 |
| 4D-150 | 4D Molecular Therapeutics | Phase 3 |
| ONS-5010 / LYTENAVA™ (bevacizumab-vikg) | Outlook Therapeutics | Approved |